EUCTR2011-005437-39-NL进行中（未招募）1 期
A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy: T-DM1 - ZEPHIR
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The patient must have histologically confirmed HER2 positive invasive carcinoma of the breast in the reference laboratory of the participating center. HER2 positive criteria to be applied are those used in the participating countries:
- •Belgium: FISH amplification ratio ? 2 in the reference laboratory of the participating center
- •The Netherlands: IHC 3+ or FISH ratio ?2 in the reference laboratory of the participating center
- •2.The patient must have documented progressive disease and present with at least 2 non-bone target” metastatic lesions, unequivocally of neoplastic origin with
- •a transaxial diameter greater than 2 cm on the screening diagnostic CT/MRI for all non-bone lesions except lymphnodes
- •a short axis greater than 1,5 cm for lymphnodes on the screening diagnostic CT/MRI
- •These two lesions should not be confluent with adjacent lesions and not have been irradiated previously.
- •3.A concurrent biopsy of a metastatic site is mandatory (with two formalin fixed paraffin embedded (FFPE) core sample and two snap frozen tumor sample) after progression has been documented and before inclusion and the patient agrees with the procedure.
- •4.Primary tumor blocks (or 11 unstained slides) available for confirmatory central laboratory HER2 testing in Institut Jules Bordet. If available, a snap frozen sample of the primary tumor will also be centralized in Institut Jules Bordet.
- •5.Age = 18 years
- •6.Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1
- •7.No significant cardiac history and current LVEF = 50%
- •8.Adequate organ function, evidenced by the following laboratory results:
- •Absolute neutrophil count > 1,500 cells/mm3
- •Platelet count > 100,000 cells/mm3
- •Hemoglobin > 9 g/dL
- •AST(SGOT) and ALT (SGPT) < 2.5 x ULN
- •Total Bilirubin = 1.5 x ULN unless the patient has documented Gilbert’s syndrome. Patients with known Gilbert’s Syndrome should have direct bilirubin within normal limits.
- •Serum alkaline phosphatase = 2.5 x ULN. Patients with bone metastases: alkaline phosphatase = 5 x ULN
- •Serum creatinine < 2.0 mg/dL or 177 µmol/L
- •International normalized ratio (INR) and activated partial thromboplastin time or partial thromboplastin time (aPTT or PTT) < 1.5 ? ULN (unless on therapeutic anti-coagulation except vitamin K antagonists which are prohibited in this study)
- •9.Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- •10.For women of childbearing potential a serum pregnancy test will be done (and it must be negative) and an agreement to use a highly-effective form of contraception during all the study and at least the following 7 months will be obtained.
- •11.Signed written informed consent obtained prior to any study specific procedure.
- •12.Completion of all necessary baseline surgical, laboratory and imaging investigations prior to patient inclusion (see Section 5, figure 1 and Section 10, figure 4 for the schedule of assessments).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.Patients with bone only metastases are not eligible.
- •2.Diffuse liver (=50%) involvement on imaging.
- •3.Patients with brain metastasis as the sole site of metastatic disease and/or are symptomatic or require therapy to control symptoms
- •NB: Brain metastasis are allowed provided they are asymptomatic and/or controlled by previous radiotherapy. In case of recent prior brain radiotherapy, there must be evidence on MRI imaging of brain metastatic control for at least 6 weeks since the end of radiotherapy. Moreover, the patient should be at the end of corticosteroid therapy and be clinically asymptomatic.
- •4.Current uncontrolled hypertension despite medication intake (systolic ? 150 mmHg and/or diastolic ? 100 mmHg)
- •5.Current unstable angina
- •6.History of symptomatic CHF of any New York Heart Association (NYHA) criteria or ventricular arrhythmia that requires treatment
- •7.History of myocardial infarction within the last 6 months
- •8.History of a decrease in LVEF to < 40% or symptomatic CHF with previous trastuzumab treatment
- •9.Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy
- •10.Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures)
- •11.History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those previously mentioned
- •12.Pregnant or lactating women
- •13.Concurrent, serious, uncontrolled infections or current known infection with HIV, active hepatitis B and/or hepatitis C.
- •14.Known prior severe hypersensitivity to trastuzumab
- •15.Patient who received lapatinib within the 15 days prior to 89Zr-Trastuzumab injection
- •16.Patient under a prohibited concomitant therapy, including vitamine K antagonist (see Section 7.1.7 concomitant therapy)
- •17.Patients with a peripheral neuropathy Grade 3 or higher
研究者
相似试验
进行中（未招募）
1 期
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1EUCTR2011-005437-39-BEJules Bordet Institute105
已完成
2 期
A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy: T-DM1HER2 positive breast cancer10006291Breast cancerNL-OMON43903Institut Jules Bordet55
招募中
1 期
Macrophage imaging using Ga-MMR-VHH2 in lung cancer patientsEUCTR2021-005575-40-BEZ Brussel20
已完成
2 期
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced FibrosisNonalcoholic SteatohepatitisNCT02421094Galectin Therapeutics Inc.30
进行中（未招募）
1 期
Phase II multicenter study of UV irradiation with UvadexTM outside of the body plus standard steroid treatment for high risk acute Graft-versus-Host Diseaseew onset high risk acute GvHD following allogeneic SCTMedDRA version: 20.0Level: LLTClassification code 10018653Term: Graft-versus-host disease <GVHD>System Organ Class: 10021428 - Immune system disordersEUCTR2019-000894-22-ATDepartment of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf72